American Health Packaging is recalling 973 cartons of Raloxifene Hydrochloride (60 mg), a prescription medication used to treat or prevent osteoporosis and reduce the risk of invasive breast cancer. The recall was issued because the tablets failed dissolution testing during stability checks, meaning the medication may not break down properly in the body as intended. This defect could potentially reduce the effectiveness of the drug for patients relying on it for treatment.
Low dissolution results mean the medication may not be absorbed into the bloodstream correctly, which can lead to a lower-than-intended dose and reduced clinical benefit for the patient. No specific injuries or adverse events have been reported at the time of this recall.
Contact healthcare provider and return product.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.